Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy

Human Gene Therapy

Volumn 24, Issue 10, 2013, Pages 824-839

  De Oliveira, Satiro Nakamura ^a   Ryan, Christine ^a   Giannoni, Francesca ^a   Hardee, Cinnamon L ^a   Tremcinska, Irena ^a   Katebian, Behrod ^a   Wherley, Jennifer ^a   Sahaghian, Arineh ^a   Tu, Andy ^a   Grogan, Tristan ^b   Elashoff, David ^b   Cooper, Laurence J N ^c   Hollis, Roger P ^a   Kohn, Donald B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LENTIVIRUS VECTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER CELL; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; GENE TRANSFER; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LYMPHOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN;

ANIMALS; ANTIGENS, CD19; CELL DIFFERENTIATION; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GENE ORDER; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE, TRANSGENIC; MYELOID CELLS; NEOPLASMS; RECEPTORS, ANTIGEN; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 84885397947     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.202     Document Type: Article

References (42)

1. Altvater, B., Landmeier, S., Pscherer, S., et al. (2009). 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin. Cancer Res. 15, 4857-4866.
2. Biglari, A., Southgate, T.D., Fairbairn, L.J., and Gilham, D.E. (2006). Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo. Gene Ther. 13, 602-610.
3. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
4. Cooper, L.J., Topp, M.S., Serrano, L.M., et al. (2003). T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101, 1637-1644.
5. Cooper, A.R., Patel, S., Senadheera, S., et al. (2011). Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J. Virol. Methods 177, 1-9.
6. Croxtall, J.D. (2011). Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma. Drugs 71, 885-895.
7. De Smedt, M., Taghon, T., Van de Walle, I., et al. (2007). Notch signaling induces cytoplasmic CD3e expression in human differentiating NK cells. Blood 110, 2696-2703.
8. Doering, C.B., Archer, D., and Spencer, H.T. (2010). Delivery of nucleic acid therapeutics by genetically engineered hemato-poietic stem cells. Adv. Drug Deliv. Rev. 62, 1204-1212.
9. Ertl, H.C., Zaia, J., Rosenberg, S.A., et al. (2011). Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res. 71, 3175-3181.
10. Esser, R., Muller, T., Stefes, D., et al. (2012). NK cells engineered to express a GD(2)-specific antigen receptor display built-in ADCC-like activity against tumor cells of neuroectodermal origin. J. Cell. Mol. Med. 16, 569-581.
11. Gaines, P., and Berliner, N. (2005). Differentiation and characterization of myeloid cells. Curr. Protoc. Immunol. Chapter 22:Unit 22F.5.
12. Gaspar, H.B., Cooray, S., Gilmour, K.C., et al. (2011). Hemato-poietic stem cell gene therapy for adenosine deaminase-defi-cient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med. 3, 97ra80.
13. Giannoni, F., Hardee, C.L., Wherley, J., et al. (2013). Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol. Ther. 21, 1044-1054.
14. Halene, S., Wang, L., Cooper, R.M., et al. (1999). Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 94, 3349-3357.
15. Hege, K.M., Cooke, K.S., Finer, M.H., et al. (1996). Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. J. Exp. Med. 184, 2261-2269.
16. Hombach, A., Hombach, A.A., and Abken, H. (2010). Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 17, 1206-1213.
17. Kane, K.L., Ashton, F.A., Schmitz, J.L., and Folds, J.D. (1996). Determination of natural killer cell function by flow cytome-try. Clin. Diagn. Lab. Immunol. 3, 295-300.
18. Kitchen, S.G., Levin, B.R., Bristol, G., et al. (2012). In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog. 8, e1002649.
19. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102.
20. Kohn, D.B., and Candotti, F. (2009). Gene therapy fulfilling its promise. N. Engl. J. Med. 360, 518-521.
21. Kohn, D.B., Dotti, G., Brentjens, R., et al. (2011). CARs on track in the clinic. Mol. Ther. 19, 432-438.
22. Kohn, D.B., Pai, S.Y., and Sadelain, M. (2013). Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. Biol. Blood Marrow Transplant. 19, S64-S69.
23. Kowolik, C.M., Topp, M.S., Gonzalez, S., et al. (2006). CD28 cost-imulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66, 10995-11004.
24. Kruschinski, A., Moosmann, A., Poschke, I., et al. (2008). Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc. Natl. Acad. Sci. USA 105, 17481-17486.
25. Lesterhuis, W.J., Haanen, J.B., and Punt, C.J. (2011). Cancer im-munotherapy-revisited. Nat. Rev. Drug Discov. 10, 591-600.
26. Naldini, L., Blomer, U., Gallay, P., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
27. Pegram, H.J., Jackson, J.T., Smyth, M.J., et al. (2008). Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J. Immunol. 181, 3449-3455.
28. Porter, D.L., Levine, B.L., Kalos, M., et al. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
29. Rappeport, J.M., O'Reilly, R.J., Kapoor, N., and Parkman, R. (2011). Hematopoietic stem cell transplantation for severe combined immune deficiency or what the children have taught us. Hematol. Oncol. Clin. North Am. 25, 17-30.
30. Roberts, M.R., Cooke, K.S., Tran, A.C., et al. (1998). Antigen-specific cytolysis by neutrophils and NK cells expressing chi-meric immune receptors bearing zeta or gamma signaling domains. J. Immunol. 161, 375-384.
31. Sanburn, N., and Cornetta, K. (1999). Rapid titer determination using quantitative real-time PCR. Gene Ther. 6, 1340-1345.
32. Savoldo, B., Ramos, C.A., Liu, E., et al. (2011). CD28 costimula-tion improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826.
33. Seely, A.J., Pascual, J.L., and Christou, N.V. (2003). Science review: cell membrane expression (connectivity) regulates neu-trophil delivery, function and clearance. Crit. Care 7, 291-307.
34. Swain, S.D., Rohn, T.T., and Quinn, M.T. (2002). Neutrophil priming in host defense: role of oxidants as priming agents. Antioxid. Redox Signal. 4, 69-83.
35. Tomayko, M.M., and Reynolds, C.P. (1989). Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148-154.
36. Tran, A.C., Zhang, D., Byrn, R., and Robert, M.R. (1995). Chi-meric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J. Immunol. 155, 1000-1009.
37. Uckun, F.M., Jaszcz, W., Ambrus, J.L., et al. (1988). Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71, 13-29.
38. Vatakis, D.N., Koya, R.C., Nixon, C.C., et al. (2011). Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 108, E1408-E1416.
39. Walker, W., Aste-Amezaga, M., Kastelein, R.A., et al. (1999). IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-gamma. J. Immunol. 162, 5894-5901.
40. Wang, X., Rosol, M., Ge, S., et al. (2003). Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood 102, 3478-3482.
41. Zarour, H.M., and Ferrone, S. (2011). Cancer immunotherapy: progress and challenges in the clinical setting. Eur. J. Immunol. 41, 1510-1515.
42. Zufferey, R., Nagy, D., Mandel, R., et al. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871-875.